Search

Author/Creator Maris, Michael

3. Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes. Issue 6 (17th January 2017)

Authors:
Garcia‐Manero, Guillermo; Montalban‐Bravo, Guillermo; Berdeja, Jesus G.; Abaza, Yasmin; Jabbour, Elias; Essell, James; Lyons, Roger M.; Ravandi, Farhad; Maris, Michael; Heller, Brian; DeZern, Amy E.; Babu, Sunil; Wright, David; Anz, Bertrand; Boccia, Ralph; Komrokji, Rami S.; Kuriakose, Philip; R...
Journal:
Cancer
Issue:
Volume 123:Issue 6(2017)
Page Start:
994
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. (2nd March 2015)

Authors:
Swords, Ronan T.; Erba, Harry P.; DeAngelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Hélène; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.
Journal:
British journal of haematology
Issue:
Volume 169:Number 4(2015:May)
Page Start:
534
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗